Business Wire·Oct 27, 2025, 6:00 AM ET

Revvity Announces Financial Results for the Third Quarter of 2025

Revvity, Inc. reported third-quarter 2025 revenue of $699 million, representing 2% year-over-year growth with 1% organic growth.
GAAP earnings per share were $0.40, while adjusted EPS from continuing operations was $1.18.
The company reaffirmed its full-year 2025 organic growth guidance of 2% to 4% & raised its adjusted EPS guidance to a range of $4.90 to $5.00.
Revvity authorized a new two-year $1 billion share repurchase program, replacing the prior program announced in October 2024.
Full-year 2025 revenue guidance was updated to $2.83-$2.88 billion to reflect recent foreign currency exchange rate changes.
Life Sciences segment revenue was $343 million with 1% growth & flat organic revenue, while adjusted operating margin was 29.5%.
Diagnostics segment revenue was $356 million with 3% growth & 2% organic growth, while adjusted operating margin was 25.1%.
The company will host a webcast on October 27, 2025, at 8:00 a.m. Eastern Time to discuss results & business outlook.
GAAP operating income from continuing operations decreased to $82 million from $98 million in the prior year period.
Adjusted operating income was $182 million, down from $193 million in the same period last year.